Replies to post #2521 on Enanta Pharmaceuticals Inc (ENTA)

[Jake2234]

“Key secondary endpoints evaluating virologic effect were not met. No difference was observed between patients treated with EDP-235 and placebo in viral RNA decline or infectious viral load, likely due to the rapid viral decline in the placebo arm of this trial’s seropositive, standard risk population. “

Let’s see how long this management team can milk that $450M for.

[DewDiligence]

ENTA—It looks like the 400mg (higher) dose will be the one to be advanced to phase-3, although the PR does not explicitly say this.

This was just confirmed by ENTA’s CEO on the CC.